Heart failure & cardiomyopathies

Frailty Patterns, Reversibility, and Outcomes With a Magnetically Levitated Left Ventricular Assist Device

JACC Heart FailPublished Pooled analysis of the MOMENTUM 3 trial portfolio and ARIES-HM3 trial

Pooled result · MortalityResult — go to the resultHazard ratio 6.26 95% CI 2.32–16.90

Authors' conclusion

Frailty is highly prevalent among patients undergoing LVAD implantation but is often dynamic and partially reversible after restoration of circulatory support.

Study context

Population
HeartMate 3 left ventricular assist device (LVAD) recipients with advanced heart failure (HF)
Participants
2,724 participants
Comparison
Frailty severity categories
Outcome
Composite of:
  • Death
  • Hemocompatibility-related adverse events
  • Renal dysfunction
  • Right HF

Pooled result

Mortality

Hazard ratio

6.26

95% CI 2.32–16.90

Severely frail vs Nonfrail
HR 6.26 (95% CI 2.32–16.90)

As reported in the abstract

Frailty at baseline
95%

Further pooled results

OutcomeRate ratio (95% CI)
Frailty reversibility after LVAD implantation · 3 months · subsequent primary endpoint0.53 (0.36–0.79)
Frailty reversibility after LVAD implantation — Recovery to a nonfrail state
15%

Frailty reversibility after LVAD implantation · 3 months

Greatest absolute frailty reductions with severe baseline frailty

Multivariable model predicting recovery from frailty

AUC
0.78-0.81

Original publication

Frailty Patterns, Reversibility, and Outcomes With a Magnetically Levitated Left Ventricular Assist Device. JACC Heart Fail. Published 1 September 2026. doi:10.1016/j.jchf.2026.103313

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.